Ponatinib for Advanced Medullary Thyroid Cancer

Stopped Recruiting halted prematurely and will not resume. New study to open soon.

Conditions

• Thyroid Neoplasms

Interventions

• DRUG: Ponatinib

Sponsor

National Institutes of Health Clinical Center (CC)

Collaborators

• [object Object]